|[December 28, 2012]
Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate
ROCKVILLE, Md. --(Business Wire)--
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has
signed a license agreement with VaxInnate Corporation under which
Emergent acquired the exclusive right to manufacture and sell
VaxInnate's pandemic influenza vaccine candidate in the United States.
The product candidate, a recombinant vaccine, has the potential to be
produced quickly, at high yields and in a cost-effective manner. This
license enables Emergent to fulfill the requirement to secure a pandemic
influenza vaccine candidate under its contract with the Biomedical
Advanced Research and Development Authority (BARDA), which established
Emergent as a Center for Innovation in Advanced Development and
Manufacturing (Center) in June 2012. VaxInnate will continue to develop
its pandemic influenza vaccine candidate under its current BARDA
contract and Emergent will manufacture the pandemic influenza vaccine
candidate using flexible manufacturing technology.
"This transaction, which secures manufacturing rights to a next
generation pandemic influenza vaccine candidate, is a step towards
satisfying Emergent's commitment to BARDA as a Center for Innovation in
Advanced Development and Manufacturing," said Daniel J. Abdun-Nabi,
president and chief executive officer of Emergent BioSolutions. "Our
public-private partnership with BARDA, which taps into our core
manufacturing capabilities and infrastructure, provides a real
opportunity to make significant progress to address the nation's medical
countermeasure manufacturing requirements. We look forward to continuing
to work with BARDA to achieve that important goal."
As a Center, Emergent is required to acquire intellectual property
rights for a pandemic influenza vccine candidate and to obtain facility
licensure to manufacture a pandemic influenza vaccine under contract
HHSO100201200004I, funded by the Biomedical Advanced Research and
Development Authority of the U.S. Department of Health and Human
About Emergent BioSolutions Inc.
Emergent BioSolutions is a specialty pharmaceutical company seeking to
protect and enhance life by offering specialized products to healthcare
providers and governments to address medical needs and emerging health
threats. Additional information may be found at www.emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, prospects, plans
and objectives of management, and any other statements containing the
words "believes", "expects", "anticipates", "intends", "plans",
"estimates" and similar expressions, are forward-looking statements.
These forward-looking statements are based on our current intentions,
beliefs and expectations regarding future events. We cannot guarantee
that any forward-looking statement will be accurate. Investors should
realize that if underlying assumptions prove inaccurate or unknown risks
or uncertainties materialize, actual results could differ materially
from our expectations. Investors are, therefore, cautioned not to place
undue reliance on any forward-looking statement. Any forward-looking
statement speaks only as of the date of this press release, and, except
as required by law, we do not undertake to update any forward-looking
statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company's
actual results to differ materially from those indicated by such
forward-looking statements, including the success of our ongoing and
planned preclinical studies and clinical trials; the rate and degree of
market acceptance and clinical utility of our products; the success of
our ongoing and planned development programs; the timing of and our
ability to obtain and maintain regulatory approvals for our product
candidates; our commercialization, marketing and manufacturing
capabilities and strategy; and our estimates regarding expenses, future
revenue, capital requirements and needs for additional financing. The
foregoing sets forth many, but not all, of the factors that could cause
actual results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement, as well
as the risk factors identified in our periodic reports filed with the
SEC (News - Alert), when evaluating our forward-looking statements.
[ Back To Technology News's Homepage ]